Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
about
Trabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesTrabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironmentTargeting tumor-associated macrophages to combat pancreatic cancerManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinMacrophage plasticity and polarization: in vivo veritasPhase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodellingThe Dual Complexity of PTX3 in Health and Disease: A Balancing Act?Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma ModelsClinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Tumor associated macrophages and neutrophils in tumor progression.Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.Advances in the targeted therapy of liposarcoma.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancerPathogen recognition by the long pentraxin PTX3.Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathwayA comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer.Solid tumor differentiation therapy - is it possible?Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.The immune network in thyroid cancerClinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma.Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function.Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic osteolysis by inducing long pentraxin 3.Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Liposarcoma: molecular genetics and therapeutics.Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.Cancer-promoting tumor-associated macrophages: new vistas and open questions.Macrophages in cancer and infectious diseases: the 'good' and the 'bad'.Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
P2860
Q26745502-3F1DDDD1-167A-4901-B75D-9E5D7692AE78Q26851658-AA658162-0B4A-4333-9646-C8E85D708424Q28076103-8638792E-9C88-4F42-B138-EAEF6C793B94Q28087771-171F1129-0649-4B8E-8F43-324327F8889DQ29547620-4B177120-F086-470F-8768-708F0A50974DQ33428382-E27BE746-F4F9-4AF9-B3A7-518A3366F7FAQ33442984-884C3DE4-77F4-4413-954F-28B21547081FQ33617922-98F3A097-D9B0-460E-A03A-CBC0D56501EEQ33632041-0EE334DF-7BCD-4832-889C-493282C854D2Q33632047-9DE99555-2063-4DB2-AD32-8E5139BC1574Q33649056-3AC8EA35-D11B-4F8E-95FD-6ACE7843266CQ33921802-D8A6CD3F-110F-4D9F-B5DE-B8B9C33CE066Q34306107-9A9A306A-79DE-44EF-B1A2-7CD252D9B194Q34650482-DD99B39F-5310-4770-BDF5-75EBAEAEC908Q34736667-8BCE9192-65CD-4787-AA21-05295196DCCBQ34898364-81E1ECBF-46CF-4B4D-A57A-13BFB14920D9Q34952133-354952C7-B402-4931-AD11-EA77D3842896Q34996149-92B36473-141B-4E7E-A1F3-0B7C2450E2F5Q35054493-596EA698-4250-4743-8C33-A0AECBE2E265Q35131481-D8E26E49-6416-4997-AA71-24B2ED0822D6Q35246995-1BFF943B-C85E-4777-B3D0-5DC8C2AA9068Q35582297-502B747B-310D-422C-9BB6-BB7AF263DCD4Q35898258-C7B7944C-2D3C-46EA-8923-873020814A98Q35918276-47C1C736-7E3A-4BF2-8B9D-BD058F7E843EQ36071880-949C1F8A-3733-46DC-8E34-EADC02E73B69Q36414357-16414E6D-104C-475B-9351-7CA528BBA98CQ37079138-B1A7C961-5A4B-42D3-BA92-32CD8CFC856FQ37081859-51E7779C-2B7B-464E-A5BB-D6C0C81AF192Q37148134-E3890B99-5439-4C5A-AC7E-DA958F3443E2Q37214309-FAFE8796-ECB3-4489-8CA9-20423EA63529Q37350801-E5AA213D-CC79-4324-A2DD-617E1C13BDA1Q37660315-840A2C2F-E7DD-4849-903F-A8E483FF5FCAQ37688261-321BA29A-CD63-4D91-BB1E-E7F7155A3DA9Q37829504-7FADDE43-703B-4F03-ADBF-9927C8F4205AQ37831160-3B0292DD-406C-4BE6-9E75-CB1E922381B6Q37901025-830A6C91-54FA-4466-B0F3-5C9F86253B05Q37930487-6B30BD18-722D-4DF8-844E-402394B35B64Q37939626-74AB8ADB-7CC3-40A8-9942-F6A8607939CAQ37945300-71B1582D-0300-43E9-A2F1-C518EA2CFCE6Q37974937-F0E10CD4-EFEA-48D9-85FC-D4BCF04B634D
P2860
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@ast
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@en
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@nl
type
label
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@ast
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@en
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@nl
prefLabel
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@ast
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@en
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
@nl
P2093
P50
P1433
P1476
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells
@en
P2093
Carlos Maria Galmarini
Emanuela Virdis
Eugenio Erba
Eva Tarantino
Fabio Pasqualini
Federica Grosso
Giovanni Germano
Juan Carlos Tercero
Matteo Simone
Michele Tavecchio
P304
P356
10.1158/0008-5472.CAN-09-2335
P407
P50
P577
2010-03-09T00:00:00Z